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obesity. Higher thresholds are needed to avoid false positive diagnoses
in obese patients with suspected pulmonary or pericardial diseases.
Further study involving diseased and healthy obese populations is
needed to fully define the optimal diagnostic values for an
abnormal PP.
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Diabetes Lowers Six-Minute Walk Test Performance in Heart Failure
To the Editor: Tibb et al. (1) have recently observed that patients
with diabetes mellitus and left ventricular systolic dysfunction
(LVSD) have a lower peak oxygen uptake p˙VO2 than patients with
LVSD alone. Peak oxygen uptake provides important information
on risk stratification and can be used to guide management (2).
However, tests involve cycling- or walking-based protocols of
increasing speed, gradient, or resistance, are not well tolerated in
some patients with LVSD. Equipment for measuring metabolic
gas exchange is expensive and cumbersome, and availability of
trained staff is limited. The six-minute walk test (6-MWT) is an
alternative and widely used method of assessing functional capac-
ity; it is simple and cost effective to perform, it is safe because
patients are self-paced during exertion, and previous reports
suggest it is a reliable test provided it is well standardized in
patients with heart failure (3). However, to our knowledge the
impact of diabetes mellitus on 6-MWT performance has not been
investigated previously.
Patients were recruited from a local community heart failure
clinic; inclusion criteria were: stable medical therapy and evidence
of LVSD, defined as a left ventricular ejection fraction (LVEF) of
40%. Exclusion criteria were: inability to walk without assistance
from another person (not including mobility aids), chronic ob-
structive pulmonary disease (COPD) of at least moderate severity
(1-s forced expiratory volume 70% of predicted, exertional
angina, systolic blood pressure 160 mm Hg or diastolic blood
pressure 90 mm Hg, participation in an exercise training program,
and active tobacco use. Severe renal dysfunction was defined as an
estimated glomerular filtration rate of 30 ml·min·1.73 m2). The
Hull and East Riding Ethics Committee approved the study, and
all patients provided informed consent for participation. Patients
who met the inclusion/exclusion criteria underwent clinical history
and physical examination, together with electrocardiogram, echo-
cardiogram, and routine blood samples. Glycosylated hemoglobin
was measured in all patients. The 6-MWT was conducted following
a standardized protocol after usual medication (4). A flat obstacle-
free corridor, with chairs placed at either end, was used. Patients
were instructed to walk as far as possible, turning 180° every 15 m
in the allotted time.
The 6-MWT performance was compared in diabetics and
nondiabetics using the independent-samples t test. To explore the
relation between 6-MWT and potential predictor variables, can-
didate variables were assessed using univariate and multivariable
regression. For the final statistical model, the goodness-of-fit was
assessed by calculating the explained variance and by plotting the
residuals. A multivariable building process was used to identify the
“best set” of predictor variables using routinely collected data,
including diabetic state, hemoglobin, N-terminal portion of pro-
brain natriuretic peptide (NT-proBNP), hypertension, ischemic
heart disease (IHD), severe renal impairment, atrial fibrillation
(AF), LVEF, and glycosylated hemoglobin.
We recruited our patients using the same process as Tibb et al.
(1). We first identified 256 patients with chronic heart failure
(CHF) and diabetes among the 756 patients with LVEF of 40%
in our clinic. We then matched these patients for age and sex to the
remaining 500 nondiabetic patients. Patients were case-matched to
the nearest single decimal place. We found age and gender
matches for 88 patients, who were selected as our patient cohort.
The 6-MWT performance was lower in diabetic (238  124 m)
than in nondiabetic patients (296  131 m) (p  0.005) (Fig. 1).
Figure 1. Six-minute walk test (6-MWT) performance in diabetic and
nondiabetic patients with left ventricular systolic dysfunction. Median,
interquartile range, and outliers are shown. *Significant difference in
6-MWT performance between diabetics and nondiabetics (p  0.005).
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Diabetic state remained an independent predictor of impaired
6-MWT performance after controlling for hemoglobin, NT-
proBNP, hypertension, IHD, severe renal impairment, AF, LVEF,
and glycosylated hemoglobin. Ischemic heart disease was more
prevalent in our diabetic patients than in nondiabetics (Table 1).
Glycosylated hemoglobin was also higher in the diabetic patients
(p  0.001). Stature, body mass index (BMI), hemoglobin,
NT-proBNP, COPD, hypertension, renal impairment, AF, and
CHF medication were similar in both groups.
To our knowledge, our study is the first to show that patients
with diabetes mellitus and LVSD are likely to have impaired
6-MWT performance compared with patients with LVSD alone.
We acknowledge the retrospective nature of the study is a
limitation. These data extend previous findings that have examined
p˙VO2 only in patients with CHF and diabetes mellitus (1,5,6).
Whereas p˙VO2 is a strong prognostic indicator (7), maximal
exercise testing cannot be tolerated by some patients with symp-
tomatic heart failure. The relative exercise intensity required to
perform the 6-MWT is lower, and it is simple and cost effective to
perform. Our findings relate to a larger and more controlled
patient population than previous investigations. Others have
shown p˙VO2 was significantly lower in diabetic than in nondiabetic
patients (1,6). Tibb et al. (1) recruited slightly fewer patients with
diabetes (n  78). We recruited older patients with a higher BMI,
glycosylated hemoglobin, and prevalence of AF. Conversely, our
patients had a lower prevalence of hypertension and less aggressive
diabetic and heart failure therapy.
We acknowledge that IHD was more prevalent in our diabetic
patients than in nondiabetics. To determine if IHD had influenced
our results we rematched patients to account for prevalence of
ischemia. We included only patients with IHD, and matched 50
diabetic patients (6-MWT  231  139 m) and 50 CHF patients
(6-MWT 283  126 m) (p  0.001). The mean difference in
6-MWT performance was 52 m. We reran the multivariable
analysis, and diabetic state remained an independent determinant
of poorer walking performance in patients with LVSD. Ischemic
heart disease was not included in the model and did not affect
6-MWT performance.
To determine if our conclusions were similar if we adjusted the
analysis in the complete patient cohort (n  256), we reanalyzed
the data, adjusting for diabetic state, hemoglobin, NT-proBNP,
hypertension, IHD, severe renal impairment, AF, LVEF, and
glycosylated hemoglobin. We found that diabetic state remained
an independent determinant of poorer walking performance in
patients with LVSD. Our conclusions are not altered if we
adjusted for confounders in all of our diabetic patients.
Although 6-MWT performance is compromised in patients
with LVSD compared with aged-matched controls (8), the addi-
tion of diabetes mellitus to LVSD is likely to further reduce
patients’ functional status. In summary, diabetic patients with
LVSD have a poorer 6-MWT performance than patients with
LVSD alone. Diabetic state is an independent determinant of
poorer walking performance in patients with LVSD.
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Table 1. Clinical Characteristics
Diabetic
(n  88)
Nondiabetic
(n  88) p Value
Age (yrs) 68.6  7.9 68.6  7.9 —
Males (%) 73.7 73.7 —
Stature (m) 1.69  0.87 1.69  0.82 NSD
BMI (kg/m2) 29  5 29  5 NSD
LVEF (%) 35.0  9.5 36.0  10.0 NSD
Hemoglobin (g/dl) 13.1  1.7 13.3  15 NSD
NT-proBNP (pg/ml) 219  254 232  263 NSD
HgbA1c (%) 7.7  1.3 6.0  0.9 0.001
COPD (%) 9.2 10.5 NSD
Hypertension (%) 50.0 42.2 NSD
History of tobacco use (%) 61.8 63.6 NSD
Renal impairment (%) 18.4 17.1 NSD
Atrial fibrillation (%) 15.5 18.4 NSD
Ischemic heart disease (%) 76.3 63.2 0.04
Insulin (%) 34.5 — —
Metformin (%) 28.9 — —
Pioglitazones (%) 4.0 — —
Beta-blockers (%) 63.5 59.2 NSD
ACE inhibitor or ARB (%) 89.3 88.1 NSD
Digoxin (%) 42.3 36.9 NSD
Aspirin (%) 60.5 53.1 NSD
Statin (%) 50.0 50.0 NSD
Loop diuretics (%) 72.4 69.2 NSD
ACE  angiotensin-converting enzyme; ARB  angiotensin-receptor blocker; BMI 
body mass index; COPD  chronic obstructive pulmonary disease; HgbA1c 
glycosylated hemoglobin; LVEF  left ventricular ejection fraction; NSD  no
significant difference.
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